What Benozil Treats: Main Uses and Benefits

Benozil (Flurazepam Hydrochloride) is a hypnotic agent commonly used to help with the symptomatic management of insomnia and related sleep-wake disturbances. It is applied across domains where additional symptomatic support is needed, particularly when symptoms create noticeable physiological strain and interfere with daily functioning. The therapeutic goal is to help manage the patterns of sleep disruption.

The medication is commonly used to help with symptoms related to difficulty in initiating sleep and impaired sleep continuity, including frequent nocturnal awakenings and severe sleep-wake disturbances. This is generally applied in contexts involving recurrent or episodic manifestations where the symptoms are pronounced.

Management of Disrupted Sleep Continuity

Benozil may be part of symptomatic management that supports sleep continuity throughout the night. This supports the patient during difficult episodes by easing distress, contributing to the possibility of an improved duration of rest to support their general well-being during symptomatic phases. It is often summarized:

“It is considered relevant for easing distress during difficult nighttime episodes, offering support toward a sustained period of rest.”

Support for Persistent Insomnia

Benozil is targeted for severe sleep-wake disturbances and persistent insomnia in adult patients. The long-acting profile provides support that may assist with maintaining a sense of stability in the sleep pattern for those who require sustained coverage to assist with maintaining the symptomatic support period, assisting with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Sleep Onset and Maintenance

Benozil is commonly used to help manage the symptom cluster where patients experience both difficulty falling asleep and frequent or sustained waking during the night, providing supportive relief for relevant symptomatic domains.

Regulatory References

1. NIH DailyMed Prescribing Information

Benozil (Flurazepam Hydrochloride) is officially restricted to use in adults. The medicine is strictly contraindicated and must not be used by specific patient groups.

These absolute exclusions apply to individuals with a known hypersensitivity to the drug or other benzodiazepines, as well as pregnant women. Use is also prohibited in patients diagnosed with myasthenia gravis, a severe liver condition, or severe impairment of respiratory function, such as significant sleep apnea syndrome.

The regulatory label states that Benozil is not currently recommended for use in persons under 15 years of age. Furthermore, use is not recommended for women who are breastfeeding, as the substance is known to appear in breast milk.

Specific patient populations require cautionary use based on their health status. This applies to patients with impaired hepatic (liver) or renal (kidney) function, pre-existing chronic pulmonary insufficiency, or a history of substance or alcohol abuse. Older adults are also a population requiring special consideration. Patients with severe depression or suicidal tendencies must also be approached with special precautions.

Interactions with other medicines and products

The official regulatory profile for Benozil (Flurazepam Hydrochloride) is defined by documented risks of pharmacodynamic reinforcement and altered metabolic clearance.

Co-administration with other Central Nervous System (CNS) depressants, including opioids, antipsychotics, and other sedative agents, results in additive CNS depressant effects. This pharmacodynamic interaction increases the documented risk of profound sedation and respiratory depression.

Administration is formally contraindicated in states of acute intoxication involving alcohol, sedative agents, or psychotropic agents.

Pharmacokinetic and Exposure Modifiers

The clearance of Flurazepam is linked to the activity of the CYP3A4 hepatic enzyme. Substances that inhibit this enzyme can increase the plasma concentration of the drug, whereas CYP3A4 inducers (such as St John's Wort) can decrease drug levels.

Timing and Population Considerations

Due to the presence of the long-acting psychoactive metabolite, N1-desalkyl-flurazepam, the potential for certain adverse interaction outcomes, including an additive effect with alcohol, is documented to persist during the day following use. The risk of interaction-related outcomes, such as oversedation and ataxia, is noted to increase substantially in elderly and debilitated patients.

Benozil (Benzoyl Peroxide) functions as a topical prodrug that penetrates the stratum corneum and is metabolized within the epithelial cells. Cleavage of the peroxide bond generates highly reactive free-radical species, specifically the benzoyloxy radical. These radicals interact non-specifically with and oxidize various biological macromolecules. The primary antimicrobial action involves non-specific peroxidation and disruption of proteins within the cell walls and membranes of the targeted bacterium, Cutibacterium acnes, leading to loss of bacterial viability. This free-radical cascade results in a system-level decrease in the cutaneous bacterial load. Additionally, Benozil exhibits keratolytic properties by interacting with keratinocytes, increasing the rate of epithelial cell turnover. This modification facilitates the disaggregation of follicular corneocytes. Furthermore, Benozil can interfere with cellular inflammatory pathways, including the inhibition of reactive oxygen species release from leukocytes and marginal inhibition of Protein Kinase C, which modulates intracellular signaling cascades related to the inflammatory response.

Benozil (Flurazepam Hydrochloride) is administered exclusively via the oral route as a capsule, available in standardized strengths of 15 mg and 30 mg. The medicine is designed to be taken once daily, with guidance specifying administration at bedtime or immediately before the patient intends to go to sleep, rather than earlier. This precise timing is integral to the product's official use.

The usual adult dosage range extends from 15 mg up to a maximum recommended dose of 30 mg, with the lower dose often being adequate for most patients. A key principle of administration involves a mandated dosage adjustment for specific populations: the initial dose for older or debilitated patients, as well as those with hepatic or renal impairment, should not exceed 15 mg. Furthermore, the drug is officially not recommended for use in the pediatric population.

Benozil is designated solely for short-term treatment. The official protocol establishes a maximum duration of use, which should not extend beyond four consecutive weeks, and this period includes any necessary gradual reduction in dosage before discontinuation (tapering). If the patient misses a dose, the instructions stipulate that the patient must not take a double dose to compensate for the missed administration. This structure defines the time-limited, dose-adjusted approach to its general administration.

Research evidence / Overview of Studies for Benozil (Flurazepam Hydrochloride)

The evidence base for Benozil is primarily based on research exploring outcomes related to temporary or persistent sleep disturbances. The available evidence base consists mainly of randomized controlled trials (RCTs), specific sleep laboratory studies, and meta-analyses, which help contextualize how the findings contribute to the broader evidence landscape for hypnotics.

Evidence for Use in Managing Sleep Initiation and Maintenance

The initial research examined short-term changes in sleep patterns using objective tools. These short-term RCTs, typically lasting from seven to 28 nights, were conducted to examine outcomes reflecting daily functioning or activity level, focusing on sleep onset and sleep continuity. Studies monitored several key objective outcomes, including the time it took to fall asleep, the total amount of time spent asleep, and the amount of time spent awake during the night. Studies reported measurements of changes in these objective outcomes during the observed time interval compared to periods when patients received an inactive placebo.

Objective vs. Subjective Outcomes in Clinical Trials

Research was applied in studies examining patient-reported experiences, such as through questionnaires or sleep diaries. This provided patient-reported outcomes describing perceived discomfort, which were then monitored in relation to the objective laboratory data. Findings describe patterns observed in the studies where objective measurements and patient-reported outcomes describing perceived discomfort did not always show equivalent change. This difference highlights an area where patient experience and physiological measurement findings were mixed.

Data on Long-Term Use and Sustained Effect

Evidence is generally limited regarding outcomes during continuous use beyond the initial short-term window of up to four weeks. As a result, long-term effects are not fully established by the core research. Research highlights that, in some studies, changes measured during the observed time interval included a reduced response in measured sleep outcomes over time.

Evidence in Special Populations

Data show patterns related to how next-day effects, such as residual drowsiness, were observed more frequently in the elderly population during studies, particularly when higher studied amounts were administered. Data for certain groups, including children or individuals with specific comorbid conditions, remain insufficient in the core research record. Research provides context but not individual predictions, reflecting that findings describe group patterns and do not determine whether an individual will respond similarly.

Key Studies & References

1. Flurazepam Hydrochloride Capsule (Benozil) NIH DailyMed Prescribing Information

Common questions about Benozil (FAQ)

Q: What if I miss a dose of Benozil?

A: Official instructions state that a double dose should not be taken to compensate for a missed administration. If the patient does not remember to take the dose until much later than the required bedtime, the dose should be skipped entirely, and the patient should resume taking the medicine at the regular time the following night.

Q: How quickly can I expect Benozil to start having an effect?

A: According to the official product information, the parent drug reaches its highest concentration in the bloodstream typically between 30 and 60 minutes after being taken. This measurement reflects the time frame associated with the drug's initial absorption.

Q: Will Benozil interact with common pain relievers like ibuprofen?

A: Regulatory documents focus primarily on interactions with Central Nervous System depressants. However, some factual documentation suggests that non-opioid pain relievers, such as ibuprofen, may decrease the rate at which the body eliminates the medicine. This could potentially lead to a higher level of the drug's concentration in the bloodstream.

Q: Are there any specific foods I need to avoid while on Benozil?

A: There are no general food prohibitions listed in official labeling. However, information for this class of medicine notes that grapefruit or grapefruit juice may interfere with how the body processes the drug. This effect is associated with potentially higher levels of the drug in the bloodstream.

Q: Can Benozil be taken at the same time as my daily vitamin?

A: Official safety information includes a general recommendation to discuss all non-prescription products with a healthcare provider prior to use. This includes common supplements like vitamins, minerals, and herbal products, as part of standard practice to address potential interactions.

Q: Does the time of day I take Benozil matter?

A: Official guidelines state that the medicine is typically taken immediately before intending to go to sleep. This precise timing is integral to the product's official use because the drug has a long-acting substance that is associated with residual effects, such as drowsiness, that persist into the following day.

Q: Can I take Benozil if I am pregnant or planning to be?

A: The medicine is contraindicated, meaning prohibited, for use in women who are already pregnant. Official labeling includes a recommendation for patients who are pregnant or planning to become pregnant to inform their healthcare provider.

Q: What safety information is available for Benozil use during breastfeeding?

A: The use of this medicine is generally not recommended during breastfeeding. This is because the drug substance is known to appear in breast milk, and due to the long-acting nature of the drug, some authoritative documentation notes the potential for infant sedation.

Q: Can I drink coffee while taking Benozil?

A: Regulatory guidance for this class of medicine suggests avoiding caffeine-containing products before sleep. Caffeine may counteract the medicine's sedative effects, potentially interfering with its action.

Q: Does Benozil show up on a standard drug test?

A: As a member of the benzodiazepine class, the drug or its related metabolites are detectable in standard drug screening tests. The amount of time it remains detectable can vary depending on the specific test and individual physiological factors.

Q: Is Benozil available over the counter or is it prescription-only?

A: Benozil is a prescription-only medication. Official regulatory classification also designates it as a controlled substance due to the potential for misuse and dependence.

Q: Do any official sources mention Benozil's use for other conditions?

A: Official documents from regulatory bodies define the primary purpose of Benozil solely as a treatment for clinically significant insomnia and related persistent sleep disturbances. The medicine is not officially indicated for other uses.

Q: Can Benozil affect my stomach or digestion?

A: Yes, documented adverse effects have included various gastrointestinal reactions. These effects have been reported to include heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, and stomach or abdominal pain.

Q: Can Benozil cause changes in mood or anxiety?

A: Documented adverse reactions have included various psychological effects. These effects have been reported to include confusion, irritability, nervousness, apprehension, and depression. Worsening of insomnia or new thinking or behavioral abnormalities may also occur.

How to Store and Dispose of Benozil (Flurazepam Hydrochloride)

Benozil capsules must be kept within the mandated temperature range and protected from environmental factors to maintain product stability. Due to its status as a controlled substance, official labeling requires heightened security measures for storage. Disposal of any unused or expired medication must follow applicable regulations, with drug take-back programs being the preferred method. The medication must not be discarded into sewers or surface water.